Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 152

Similar articles for PubMed (Select 23444271)

1.

Cost effectiveness of antiarrhythmic medications in patients suffering from atrial fibrillation.

Brüggenjürgen B, Kohler S, Ezzat N, Reinhold T, Willich SN.

Pharmacoeconomics. 2013 Mar;31(3):195-213. doi: 10.1007/s40273-013-0028-7. Review.

PMID:
23444271
2.

Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation.

Rodgers M, McKenna C, Palmer S, Chambers D, Van Hout S, Golder S, Pepper C, Todd D, Woolacott N.

Health Technol Assess. 2008 Nov;12(34):iii-iv, xi-xiii, 1-198. Review.

3.

Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.

Saborido CM, Hockenhull J, Bagust A, Boland A, Dickson R, Todd D.

Health Technol Assess. 2010 Jun;14(31):iii-iv, 1-75. doi: 10.3310/hta14310. Review.

4.

Dronedarone for the treatment of atrial fibrillation and atrial flutter.

Maund E, McKenna C, Sarowar M, Fox D, Stevenson M, Pepper C, Palmer S, Woolacott N.

Health Technol Assess. 2010 Oct;14(Suppl. 2):55-62. doi: 10.3310/hta14suppl2/08. Review.

5.

Cost-effectiveness of rhythm versus rate control in atrial fibrillation.

Marshall DA, Levy AR, Vidaillet H, Fenwick E, Slee A, Blackhouse G, Greene HL, Wyse DG, Nichol G, O'Brien BJ; AFFIRM and CORE Investigators.

Ann Intern Med. 2004 Nov 2;141(9):653-61.

PMID:
15520421
6.

Advanced electrophysiologic mapping systems: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2006;6(8):1-101. Epub 2006 Mar 1.

7.

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.

Shepherd J, Jones J, Frampton GK, Tanajewski L, Turner D, Price A.

Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. Review.

8.

Cost effectiveness of ibutilide with prophylactic magnesium in the treatment of atrial fibrillation.

Coleman CI, Kalus JS, White CM, Spencer AP, Tsikouris JP, Chung JO, Kenyon KW, Ziska M, Kluger J, Reddy P.

Pharmacoeconomics. 2004;22(13):877-83.

PMID:
15329032
9.

Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter.

Howard PA.

Ann Pharmacother. 1999 Jan;33(1):38-47. Review.

PMID:
9972384
10.
11.

Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation.

Catherwood E, Fitzpatrick WD, Greenberg ML, Holzberger PT, Malenka DJ, Gerling BR, Birkmeyer JD.

Ann Intern Med. 1999 Apr 20;130(8):625-36.

PMID:
10215558
12.

[Epidemiology and therapy of atrial fibrillation].

Capucci A, Aschieri D, Villani GQ.

Ann Ital Med Int. 1996 Oct;11 Suppl 2:5S-10S. Review. Italian.

PMID:
9004821
13.

Clinical and cost comparison of ibutilide and direct-current cardioversion for atrial fibrillation and flutter.

Murdock DK, Schumock GT, Kaliebe J, Olson K, Guenette AJ.

Am J Cardiol. 2000 Feb 15;85(4):503-6, A11.

PMID:
10728961
14.

The costs of care in atrial fibrillation and the effect of treatment modalities in Germany.

McBride D, Mattenklotz AM, Willich SN, Brüggenjürgen B.

Value Health. 2009 Mar-Apr;12(2):293-301. doi: 10.1111/j.1524-4733.2008.00416.x. Epub 2008 Jul 24.

PMID:
18657103
15.

Cost-effectiveness of atrial fibrillation catheter ablation.

Andrikopoulos G, Tzeis S, Maniadakis N, Mavrakis HE, Vardas PE.

Europace. 2009 Feb;11(2):147-51. doi: 10.1093/europace/eun342. Epub 2008 Dec 20. Review.

16.

Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation.

Eckman MH, Falk RH, Pauker SG.

Arch Intern Med. 1998 Aug 10-24;158(15):1669-77.

PMID:
9701102
17.
18.
19.

Effectiveness and costs of chemical versus electrical cardioversion of atrial fibrillation.

de Paola AA, Figueiredo E, Sesso R, Veloso HH, Nascimento LO; SOCES Investigators.

Int J Cardiol. 2003 Apr;88(2-3):157-66.

PMID:
12714194
20.

Ablation for atrial fibrillation: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2006;6(7):1-63. Epub 2006 Mar 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk